HPV Vaccines and New Vaccination Schedules Implementation
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 34
Special Issue Editors
Interests: HPV; cervical cancer; vaccination; knowledge
Interests: cervical cancer; human papillomavirus; L1 protein; VLPs; linear and conformational epitopes; HPV vaccine
Special Issue Information
Dear Colleagues,
Human papillomavirus (HPV) vaccination programs are a primary prevention strategy for cervical cancer. They have made significant progress in preventing HPV-related diseases. Countries that have implemented these vaccination efforts have observed substantial reductions in HPV-related conditions, including decreases in high-grade cervical neoplasia and genital warts. However, global coverage remains imbalanced, with notable disparities between high-income and low-income countries. While effective programs exist, they remain suboptimal, thus the World Health Organization's strategy to eradicate cervical cancer faces an uncertain future. This Special Issue aims to provide insights into HPV vaccines and the burden of HPV-related diseases, including updates on HPV vaccine efficacy, HPV-related disease prevention, the status of HPV vaccination coverage, and estimates of the time required to meet vaccination targets in various countries. It will also examine barriers to HPV vaccination and address other issues surrounding the HPV vaccine. We welcome original research articles and reviews broadly covering these topics.
Dr. Kirvis Torres-Poveda
Dr. Aurelio Cruz-Valdez
Dr. Vicente Madrid-Marina
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- papillomavirus vaccines
- vaccination schedule
- HPV vaccine efficacy
- vaccine uptake
- implementation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
